论文部分内容阅读
用化学合成的胸腺胜（Tα1）和工程菌生产的干扰素（IFNα1b）联合治疗慢性乙型肝炎50例、慢性丙肝20例。结果：联合治疗组患者HBV－DNA和HCV－RNA阴转率分别是68％和70％，较单独用IFNα1b的44％和30％的疗效好（P＜0．01）。取联合治疗组病毒标志物阴转的患者24例，检测CD、sIL－2R和TNF，发现治疗前较高，治疗后明显下降。结果表明，Tα1和IFNα1b是通过T细胞免疫和淋巴因子机制起调控治疗作用的。
Thymosin (Tα1) and interferon (IFNα1b) produced by the engineered bacteria were used to treat 50 cases of chronic hepatitis B and 20 cases of chronic hepatitis C, respectively. RESULTS: The negative conversion rates of HBV-DNA and HCV-RNA in combined treatment group were 68% and 70%, respectively, which were significantly better than those of 44% and 30% IFNα1b alone (P <0.01). Twenty-four patients with negative conversion of virus markers in combination therapy group were detected for CD, sIL-2R and TNF, and found to be higher before treatment and significantly decreased after treatment. The results show that Tα1 and IFNα1b through the T-cell immune and lymphokine mechanisms play a regulatory role in the treatment.